Referring to the results of other tumor-related studies and in combination with the patient’s BRCA1 mutation, the patient’s chemotherapy protocol was changed to GP in combination with durvalumab after disease recurrence and metastasis, at the same time, the patient was orally treated with anlotinib, which is effective for sarcoma. This evidence concerns the gene BRCA1 and sarcoma.